Blue Sail Medical Acquires NVT

June 9, 2020—Blue Sail Medical, which is headquartered in Singapore, announced the completion of its acquisition of Switzerland-based NVT AG, which was previously communicated on September 20, 2019. The deal joins NVT’s transcatheter aortic valve replacement (TAVR) technology with the interventional cardiology experience of Blue Sail's subsidiary, Biosensors International Group.

According to Blue Sail, NVT's Allegra self-expanding supra-annular TAVR system received European CE Mark approval in 2017. On April 29, 2020, the device received CE Mark approval for the valve-in-valve indication. Data presented at PCR London Valves 2019 showed positive 12-month outcomes for the Allegra system in a valve-in-valve setting in the VIVALL trial.